Cases & Deals

Opus Bio and Juno Therapeutics sign license agreement relating to CD-22 targeted cancer therapy

Clients Opus Bio, Inc.

Jones Day advised Opus Bio, Inc., a diversified biologics company, in connection with an exclusive patent licensing agreement with Juno Therapeutics, Inc., a U.S. biopharmaceutical company, covering a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. The CD22-targeted CAR T cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio, Inc. The NCI has begun enrollment in a Phase I trial evaluating pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL).

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.